Zevra Therapeutics’ (ZVRA) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock. Cantor Fitzgerald’s price target points to a potential upside of 234.00% from the company’s current price.

ZVRA has been the subject of several other research reports. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Guggenheim set a $21.00 target price on shares of Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 4th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Finally, Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $21.71.

Zevra Therapeutics Stock Down 7.2 %

Shares of ZVRA traded down $0.59 during midday trading on Wednesday, hitting $7.49. The stock had a trading volume of 281,370 shares, compared to its average volume of 390,939. The firm has a market cap of $399.52 million, a price-to-earnings ratio of -3.80 and a beta of 1.98. The company has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $8.14. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. On average, analysts anticipate that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Buying and Selling

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ZVRA. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the 4th quarter valued at $53,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at about $94,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Zevra Therapeutics during the fourth quarter worth about $94,000. Intech Investment Management LLC acquired a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $95,000. Finally, Virtu Financial LLC bought a new position in Zevra Therapeutics in the 3rd quarter valued at approximately $127,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.